ENPP2 and glaucoma: This study reports that inhibition of ATX LysoPLD activity by topical and intracameral delivery of a chemical inhibitor significantly decreases IOP, suggesting that ATX is a potential therapeutic target for lowering IOP in glaucoma patients.